ADA preview: cardio data in diabetes, drug costs and healthcare reformInvokana data could suggest cardio benefit for SGLT2 class. Share XADA preview: cardio data in diabetes, drug costs and healthcare reformhttps://pharmaphorum.com/views-and-analysis/ada-preview-new-cardio-data/